Sabbin Sakamako na gwaji na asibiti don Magani na COVID-19 Marasa lafiya

Kintor Pharmaceutical Limited, wani kamfani ne na ilimin kimiyyar halittu na asibiti wanda ke haɓaka sabbin ƙananan ƙwayoyin cuta da magungunan ilimin halitta, ya ba da sanarwar yin rajista da adadin majinyacin sa na farko a China a cikin gwajin asibiti na yankuna da yawa na yankuna III (NCT04869228) na proxalutamide don maganin COVID-19 marasa lafiya a asibitin mutane na uku na Shenzhen na kasar Sin a ranar 10 ga Fabrairu, 2022.

Gwajin lokaci na III bazuwar, makafi biyu, mai sarrafa wuribo, binciken yanki da yawa, an tsara shi don kimanta inganci da amincin proxalutamide a cikin marasa lafiya na COVID-19 na maza. Gwajin kashi na III ya shigar da kusan marasa lafiya 200 a cikin shafuka a cikin ƙasashe ciki har da Brazil, Philippines da Malaysia. Kasar Sin tana daya daga cikin manyan kasashen da ke halartar wannan gwaji na yankuna da dama, wanda hukumar NMPA ta kasar Sin ta amince da shi a ranar 1 ga Satumba, 2021. Wuraren da ke halartar wannan gwaji a kasar Sin sun hada da asibitin Beijing Ditan, asibitin sada zumunta tsakanin Sin da Japan, na uku. Asibitin mutane na Shenzhen, Cibiyar Kiwon Lafiyar Jama'a ta Shanghai, Asibitin Hangzhou Xixi, Cibiyar Kiwon Lafiyar Jama'a ta Chengdu da Asibitin Mutane na biyar na Suzhou.

Dr. Tong Youzhi, wanda ya kafa, shugaba, kuma shugaban kamfanin Kintor Pharma, ya yi tsokaci, “Muna so mu mika godiya ta musamman ga shugaban kasar Dr. Hongzhou Lu da tawagarsa a asibitin mutane na uku na Shenzhen saboda fara rajistar marasa lafiya da kuma alluran alluran rigakafi Gwajin gwaji na asibiti na kashi na uku na proxalutamide don kula da marasa lafiya na COVID-19 a kasar Sin, wanda muhimmin mataki ne ga wannan gwaji na asibiti na yankuna da yawa. Za mu yi iya ƙoƙarinmu don gayyatar ƙarin shafuka a China don shiga wannan muhimmin binciken. Bayan haka, gwajin asibiti na marasa lafiya na COVID-19 (NCT05009732) ya fara yin rajistar marasa lafiya a Amurka, Ukraine da Philippines, kuma a halin yanzu yana gudanar da gwajin marasa lafiya kafin yin rajista a wuraren a China. Har ila yau, muna ci gaba da aiwatar da tsarin a cikin sauran ƙasashen da ke shiga cikin gwaje-gwajen asibitocinmu na yankuna da yawa."